Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results

Posted by Geri Gentry on Aug 8th, 2026

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) issued its earnings results on Thursday. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80), FiscalAI reports. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 58.80%. The company had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. During the same quarter last year, the firm earned ($0.98) EPS. The company’s revenue for the quarter was down 46.4% on a year-over-year basis.

Here are the key takeaways from Intellia Therapeutics’ conference call:

Lonvo-z’s phase III HALO trial succeeded, showing an 87% reduction in mean monthly HAE attacks versus placebo, with 62% of patients attack-free and therapy-free during the six-month evaluation period. Intellia expects FDA acceptance of the rolling BLA by year-end and is preparing for a potential U.S. launch in the first half of 2027.
Nex-z phase III enrollment and dosing resumed in both ATTR trials during the second quarter after clinical holds were resolved, with screening rates increasing globally. Intellia reported that MAGNITUDE has enrolled more than 650 patients and that blinded event rates remain within its internal projections.
Intellia identified the HLA-C*05:01 allele as associated with a significantly higher rate of severe transaminase elevations following nex-z treatment. The allele is present in roughly 12% of patients, although most carriers did not experience severe elevations; updated protocols now require HLA typing and enhanced risk disclosure.
The company ended June with $628.4 million in cash, equivalents, and marketable securities after raising approximately $195 million in net proceeds through an April equity financing. Management believes this provides a cash runway into at least 2028, excluding potential lonvo-z product revenue.
Second-quarter collaboration revenue declined to $7.7 million from $14.2 million year over year, while net loss widened to $106.6 million from $101.3 million. R&D expenses fell, but G&A increased due to commercial infrastructure build-out, legal costs, and higher stock-based compensation.

Intellia Therapeutics Price Performance

Shares of NTLA traded up $0.70 during midday trading on Friday, hitting $11.94. The stock had a trading volume of 4,923,615 shares, compared to its average volume of 4,163,880. The company has a 50 day simple moving average of $13.65 and a two-hundred day simple moving average of $13.48. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -3.55 and a beta of 1.81.

Insider Buying and Selling

In other news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC bought a new stake in Intellia Therapeutics in the second quarter worth $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth about $30,000. Advisory Services Network LLC bought a new stake in Intellia Therapeutics during the third quarter worth approximately $33,000. Van ECK Associates Corp raised its holdings in Intellia Therapeutics by 104.2% during the 4th quarter. Van ECK Associates Corp now owns 5,391 shares of the company’s stock valued at $48,000 after buying an additional 2,751 shares during the period. Finally, Danske Bank A S purchased a new stake in shares of Intellia Therapeutics in the third quarter valued at $50,000. Institutional investors own 88.77% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing a favorable “nex-z hypothesis.” The upgrade suggests the firm sees greater potential in Intellia’s gene-editing pipeline, providing the clearest positive catalyst in the recent news flow. Intellia upgraded at Evercore ISI on nex-z hypothesis
Positive Sentiment: Brookline Capital Markets raised its fourth-quarter 2026 EPS forecast to a loss of $0.41 from $0.47, while projecting a path to profitability beginning in 2027. That outlook supports the longer-term investment case, although the firm made broader reductions to its estimates. Brookline Capital Markets estimates
Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating the firm sees neither a sufficiently strong near-term catalyst nor enough downside to change its stance. Bank of America Securities remains a Hold on Intellia Therapeutics
Negative Sentiment: Intellia’s second-quarter loss was in line with expectations, but revenue fell about 46% year over year to $7.66 million, missing estimates of roughly $12.98 million. The decline was attributed to lower revenue from the Regeneron collaboration, highlighting the company’s reliance on partnership income while it continues to spend heavily on research and development. NTLA Q2 earnings in line, top line misses on lower Regeneron revenues
Negative Sentiment: Brookline lowered its estimates for the second and third quarters of 2026 and reduced its full-year 2026 forecast to a $2.84 per-share loss. More significantly, projected EPS was cut for 2027 through 2030, including a reduction in 2030 estimates from $68.52 to $25.07, signaling lower expectations for the eventual commercial opportunity.
Negative Sentiment: WallStreetZen downgraded NTLA to Strong Sell, adding to the bearish analyst commentary and reinforcing concerns about continued losses, execution risk and valuation. Intellia lowered to Strong Sell rating

Analyst Upgrades and Downgrades

NTLA has been the topic of several analyst reports. The Goldman Sachs Group increased their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th. Chardan Capital upped their target price on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Morgan Stanley raised their price target on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. Finally, Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and a consensus target price of $20.85.

Check Out Our Latest Analysis on Intellia Therapeutics

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.